Phase 2 Study of the Safety and Efficacy of UK-500,001 in Adult Patients With COPD

• Status: Terminated
• Trial end date: 2006-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This initial proof of concept, phase II study aims to assess the safety and efficacy of UK-500,001 for the chronic maintenance treatment of adults with Chronic Obstructive Pulmonary Disease.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer

Criteria

Inclusion Criteria:

• Moderate-severe COPD (Global inititiative for chronic Obstructive Lung Disease, GOLD, 2003 definition)

• Smoking history of at least 10 pack-years

Exclusion Criteria:

• Any significant co-morbid disease

• Use of any maintenance therapy except short acting bronchodilators